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Original Investigation/Özgün Araştırma
The Evaluation of Clinical Signs in Patients with Suspected 
Renovascular Hypertension 
Renovasküler Hipertansiyon Şüphesi Olan Hastalarda Klinik 
İpuçlarının Değerlendirilmesi
doi: 10.5262/tndt.2018.1001.03
ABSTRACT
OBJECTIVE: Renovascular hypertension (RVH) is the most common yet correctable cause of 
secondary hypertension if diagnosed early. There are many clinical signs that can suggest RVH. The 
aim of this study was to find which clinical or laboratory signs are more indicative in diagnosing RVH 
and in determining which patients should go through renal angiography.
MATERIAL and METHODS: The study included 184 patients who presented to our clinic due to 
hypertension and were under risk of RVH. All patients underwent three-dimensional time-of-flight 
Magnetic Resonance Angiography with phase-contrast. The patients were divided into two groups as 
with and without renal artery stenosis, supported by MRA. 
RESULTS: Advanced age, low body mass index, high serum creatinine level, presence of proteinuria, 
and patients with diabetes mellitus and coronary artery disease were found to be significant risk factors 
for RVH. Only the presence of renal asymmetry and the history of coronary artery disease were found 
to be independent risk factors.
CONCLUSION: In conclusion, detailed patient history and the evaluation of renal size are very 
important for patients with hypertension. Coronary artery disease and a difference in renal size of more 
than 1.5 cm could be strong indicators of RVH. 
KEY WORDS: Renovascular hypertension, Renal artery stenosis, Magnetic resonance angiography 
ÖZ
AMAÇ: Renovasküler hipertansiyon (RVH); erken teşhis edildiğinde sekonder hipertansiyonun 
en fazla düzeltilebilme ihtimali olan nedenlerinden biridir. RVH’u destekleyen pek çok klinik ipucu 
bulunmaktadır. Çalışmanın amacı, RVH tanısında, klinik ve laboratuvar ipuçlarından hangilerinin daha 
belirleyici olduğunu bulmak ve renal anjiyografi yapılması gereken hastaları belirlemektir.
GEREÇ ve YÖNTEMLER: Çalışmaya hipertansiyon nedeni ile başvuran ve RVH için risk faktörü 
taşıyan 184 hasta dahil edildi. Tüm hastalara üç boyutlu kontrastlı manyetik rezonans anjiyografi 
(MRA) uygulandı. Hastalar MRA sonucuna göre; renal arter stenozu olanlar ve olmayanlar şeklinde 
iki gruba ayrıldı.  
BULGULAR: İleri yaş, düşük vücut kitle indeksi, yüksek serum kreatinin seviyesi, proteinüri, diabetes 
mellitus ve koroner arter hastalığı varlığı, RVH için önemli risk faktörleri olarak bulundu. Koroner arter 
hastalığı öyküsü ile renal asimetri varlığı bağımsız risk faktörü olarak saptandı. 
SONUÇ: Sonuç olarak, ayrıntılı öykü alınması ve böbrek boyutunun değerlendirilmesi hipertansiyon 
hastaları için büyük önem taşımaktadır. Koroner arter hastalığı ve böbrek boyutları arasında 1.5 cm’den 
büyük fark, RVH’nun güçlü birer göstergesi olabilir. 
ANAHTAR SÖZCÜKLER: Renovasküler hipertansiyon, Renal arter stenozu, Manyetik rezonans 
anjiyografi
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INTRODUCTION
Renovascular hypertension (RVH) is a clinical situation 
characterized by high blood pressure (BP) resulting from renal 
ischemia in the presence of stenosis of the the renal artery or 
arteries (RAS) (1). It is the most common yet correctable cause 
of secondary hypertension and closely associated with chronic 
renal failure, increased cardiovascular mortality, and end organ 
damage (1-5). The prevalence of RVH varies with the clinical 
settings. It is about 1-5% in all the hypertensive population, less 
than 1% in patients with mild-moderate high blood pressure, and 
between 10-45% in patients with severe, malignant or resistant 
hypertension (1-10)
Although renal angiography is the gold standard for the 
diagnosis of RAS, it is an invasive and costly method. Due to 
the risks associated with contrast nephropathy, angiography is 
recommended for patients at high risk for RVH (1, 4). MRA 
is being increasingly used as the fist line screening test for 
RVH (10). Compared with DSA, MRA has median sensitivity 
and specificity of 90-96% and 76-94%, respectively (7,10). 
There are many clinical signs that can suggest RVH. However, 
no single sign is useful to determine patients at high risk for 
RVH. There is a commonly used clinical risk index for RVH 
(Table I) (5, 10-15). In this study, the aim was to find which 
clinical or laboratory signs are more indicative in the diagnosis 
of RVH and to determine which patients should go through renal 
angiography.
MATERIAL and METHODS
In our clinic, renal MRA examination is routinely required 
for admitted patients suspected of renovascular hypertension. In 
addition, we obtain informed consent from each patient before 
the MRA examination. 
This study was approved by the Baskent University 
Institutional Review Board (Project no: KA 17/170). The 
study included 184 patients who presented to our clinic due to 
hypertension and had risk factor(s) for RVH between October 
2007 and March 2009. Of these patients, 77 were male (42%) 
and 107 were female (58%) (mean age ± SD: 53.5 ± 14 years). 
Patient demographics (age, gender, body mass index 
(BMI), medical history (duration of hypertension, number of 
antihypertensive drugs, presence of diabetes mellitus (DM), 
coronary artery disease (CAD) and peripheral arterial disease 
(PAD), smoking habits, mean BP), laboratory values (serum 
creatinine, potassium, low density lipoprotein-cholesterol 
(LDL- cholesterol), triglycerides (TG), and uric acid levels in 
blood, and presence of proteinuria (Table II), were recorded. All 
patients were assessed by the clinical risk index (Table I).
Blood pressure was measured three times with at least one 
week interval by standard sphygmomanometer. Measurements 
were taken from patients in the sitting position, with the back 
supported and the arm supported at the heart level, after resting 
for 5 minutes without speaking. The last two measured blood 
pressure values were averaged and recorded. Patients with a 
Table I: Clinical Risk Index for Renovascular Hypertension (adapted from reference 11: 2005 ACC/AHA practice guidelines).
1 Onset of severe or stage II hypertension (blood pressure ≥ 160/100 mmHg) after the age of 55 years.
2 Refractory or resistant hypertension, defined as inadequate blood pressure control in a patient who are taking to therapeutic doses of three appropriate antihypertensive agents (including a diuretic).
3 Severe hypertension with acute onset and an acute rise in blood pressure in patients with previously well controlled hypertension.
4 A systolic-diastolic abdominal bruit that lateralizes to one side.
5 Patients with diffused atherosclerosis (coronary, peripheral arterial), particularly those over age 50 with stable creatinine level.
6 Onset of hypertension before the age of 30 years, particularly if there is a negative family history and no other risk factors for hypertension.
7 Patient with diffuse atherosclerosis with progressively increasing creatinine levels.
8 Malignant hypertension (patients with signs of end-organ-damage such as acute renal failure, retinal hemorrhages or papilledema, heart failure, or neurologic disturbance).
9 An acute elevation in the plasma creatinine concentration that occurs after the beginning of therapy with an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). 
10 Unexplained creatinine elevation in patients with hypertension.
11 Patient with an unexplained atrophic kidney or asymmetry in renal sizes of > 1.5 cm.
12 Unexplained congestive heart failure or acute pulmonary edema.
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mean systolic blood pressure ≥140 mm Hg, mean diastolic blood 
pressure ≥90 mm Hg or those using antihypertensive drugs were 
recorded as patients with hypertension. The diagnosis of CAD 
was determined according to the clinical history of the patients 
(angina pectoris, acute myocardial infarction, bypass surgery, 
balloon dilatation or stent implantation in coronary arteries) and 
the results of the electrocardiography and echocardiography 
test. Patients with a fasting blood glucose level ≥126 mg/dl or 
those using antidiabetic drugs were recorded as patients with 
DM. The diagnosis of PAD was determined based on presence 
of intermittent claudication, stroke or previous endovascular 
surgery in the history of the patients and Doppler ultrasound 
signs in the lower extremity. If the patients had smoked regularly 
for at least 1 year, we considered them to be habitual smokers. 
Technical Data
The levels of glucose, creatinine, LDL- cholesterol, TG, and 
uric acid were studied by the enzymatic colorimetric method 
in Beckman Unicel DXC 800 analyzer (Beckman Coulter, 
Inc., Fullerton, CA, USA). The levels of LDL-cholesterol 
were calculated by the Friedewald formula. The concentration 
of potassium was determined by same analyzer using the ion-
selective electrode method. Protein levels in urine were studied 
by turbidimetric methods in the Hitachi 912 analyzer.
All patients with suspected RVH underwent contrast 
enhanced renal magnetic resonance angiography (MRA). MRA 
was performed using 1.5T MR systems (Avanto, Siemens, 
Erlanger, Germany). Contrast-enhanced breath-hold FISP three-
dimensional MRA was applied in the coronal view, centered at 
the renal arteries. An anterior-posterior phased-array surface 
coil (torso array coil) was used. We used sagittal, coronal, and 
axial localizing pulse sequences, followed by image acquisition 
in the coronal plane. The FLASH 3D gradient echo sequence 
was employed. The following imaging parameters were used: 
repetition time 2.8 ms; echo time 1.02 ms; flip angle 25°; field of 
view 400 mm; matrix size 256 x 512; slice thickness 1.2 mm. For 
contrast administration, an intravenous cannula was placed in an 
antecubital arm vein and connected to long extension tubing. 
We used approximately 15-20 mL (0.2 mmol/kg) of meglumine 
gadoterate (Dotarem, Guerbet, France). The contrast material 
was injected with an automatic injector at 2 mL/sec, followed 
by a 20 mL saline flush. All patients were required to hold their 
breath during image acquisition. After the extracted images 
were processed by the ‘maximum intensity projection’ method, 
they were converted into a three-dimensional image. The two- 
and three-dimensional images were evaluated separately. The 
diameter of the renal artery and the size of both kidneys were 
evaluated.
Patients were divided into two groups as with and without 
RAS. Patient with RAS were classified into two subgroups 
according to the degree of RAS as hemodynamically significant 
(≥60% diameter stenosis) and not hemodynamically significant 
(1,2,9,14,16).
Statistical Analysis
SPSS for windows 11.0 was used in statistical evaluation of 
the data (SPSS Inc., Chicago, IL, USA). Descriptive statistics 
(number, percentage and mean ± SD) were used as the statistical 
method. Parametric and nonparametric differences between 
groups were evaluated using the Student T and Mann-Whitney 
U tests. Chi-square was used to compare categorical values. 
Linear regression analysis was used to determine the possible 
risk factors associated with RAS. P value <0.05 was accepted as 
statistically significant.
RESULTS
Renal artery stenosis was found in 32% (59/184) of the 
patients with hypertension. Hemodynamically significant RAS 
was found in 21% (39/184) of all patients. Age (58.5 ± 14.5 
vs. 51 ± 13 years, respectively, p<0.01) and serum creatinine 
levels (1.6 ± 1.0 vs. 1.2 ± 0.8 mg/dl, respectively, p<0.01) 
were significantly higher while BMI (28 ± 4.4 vs. 31 ± 6 kg/
m2, respectively, p<0.01) was significantly lower in patients 
with RAS compared to those without RAS. The prevalence of 
Table II: Demographic and basal laboratory data of patients.
mean ± SD, n (%)
Age (years) 53.5± 14
Gender (male/ female) 77/107
BMI (kg/m2) 30.1 ± 5.8
Duration of hypertension (years) 8.9 ± 7.5
Number of antihypertensive drugs (n) 2.7 ± 1.2
DM n (%) 59 (32%)
CAD n (%) 40 (22%)
PAD n (%) 15 (8%)
Smoking n (%) 26 (14%)
Systolic BP (mm Hg) 165 ± 23
Diastolic BP (mm Hg) 97 ± 10
Serum creatinine (mg/dl) 1.3 ± 0.9
Potassium (mg/dl) 4.3 ± 0.5
LDL-cholesterol (mg/dl) 118 ± 33
TG (mg/dl) 167 ± 97
Uric acid (mg/dl) 6 ± 1.7
Presence of proteinuria n % 92 (50%)
BMI: Body mass index, DM: Diabetes mellitus, CAD: Coronary 
artery disease, PAD: Peripheral arterial disease, BP: Blood pressure, 
LDL-Cholesterol: Low density lipoprotein-cholesterol,
TG: Triglycerides. 
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DM (25 (42%) vs. 34 (27%), respectively, p= 0.04), CAD (23 
(39%) vs. 17 (14%) respectively, p<0.01), and proteinuria (36 
(61%) vs. 56 (45%) respectively, p=0.04) were more significant 
in patients with RAS. There were no statistically significant 
difference between the groups with respect to gender, duration of 
hypertension, number of antihypertensive drugs, PAD, smoking, 
systolic and diastolic BP, and laboratory parameters including 
serum potassium, LDL-cholesterol, TG, uric acid levels (Table 
III). The presence of the clinical risk factors including the 3rd 
(Severe hypertension with acute onset and an acute rise in BP in 
patients with previously well controlled hypertension) risk factor 
was significantly lower, while the 10th (Unexplained creatinine 
elevation in patients with hypertension) and 11th (Patient with 
an unexplained atrophic kidney or asymmetry in renal sizes of 
>1.5 cm) risk factors were significantly higher in patients with 
RAS (Table IV). CAD and the 11th risk factor of clinical risk 
index were independent variables that were associated with RAS 
in a multivariate linear regression analysis (Table V).
Hemodynamically significant RAS with MRA was detected 
in 39 patients. 33 of these 39 patients underwent DSA. 6 patients 
did not give consent for the procedure. Significant RAS was 
detected in 29 of 33 patients who underwent DSA. Of the 29 
patients undergoing revascularization, only 21 had a decrease in 
the number of antihypertensive drugs.
DISCUSSION
Although the prevalence of RAS is not known exactly, it 
has been reported to be between 7% and 45% in the literature 
according to method used for the diagnosis and the characteristic 
of the patients (1-10). Hemodynamically significant RAS was 
detected about 21% of our patients with MRA. In the literature, 
this rate was reported at between 6.3% and 23% in different 
patients groups (1-3,9,13,17). Compared with DSA, MRA 
has median sensitivity and specificity of 90-96 and 76-94%, 
respectively (7,10). We were unable to calculate sensitivity and 
specificity in our study because we did not perform DSA in 
patients without RAS according to MRA.
Advanced age has been reported as a significant risk factor 
for RAS in many studies (1,3-4,17-18). We found similar results.
The association between gender and RAS has varied in 
different studies. Similar to the studies of Ozkan and Krijnen 
(2,4), we found that gender was not a risk factor for RAS.
Table III: Distribution of patients according to the presence of renal artery stenosis.
Group without RAS
n= 125 (68%)
Group with RAS
n= 59 (32%)
p
Age (years) 51 ± 13 58.5 ± 14.5 0.01
Male % 50 (65%) 27 (35%) 0.52
BMI (kg/m2) 31 ± 6 28 ± 4.4 0.01
Duration of hypertension (years) 8.6 ± 7.5 9.5 ± 7.5 0.44
Number of antihypertensive drugs (n) 2.6 ± 1.2 2.9 ± 1.2 0.16
DM n (%) 34 (27%) 25 (42%) 0.04
CAD n (%) 17 (14%) 23 (39%) 0.01
PAD n (%) 20 (6%) 6 (10%) 0.08
Smoking n (%) 20 (16%) 6 (23%) 0.36
Systolic BP (mm Hg) 164 ± 23 166 ± 23 0.48
Diastolic BP (mm Hg) 97 ± 10 96 ± 10 0.33
Serum creatinine (mg/dl) 1.2 ± 0.8 1.6 ± 1.0 0.01
Potassium (mg/dl) 4.3 ± 0.5 4.4 ± 0.6 0.33
LDL-cholesterol (mg/dl) 116 ± 30 125 ± 39 0.43
TG (mg/dl) 170 ± 101 162 ± 89 0.60
Uric acid (mg/dl) 6 ± 1.7 6.4 ± 1.6 0.11
Presence of proteinuria n % 56 (45%) 36 (61%) 0.04
BMI: Body mass index, DM: Diabetes Mellitus, CAD: Coronary artery disease, PAD: Peripheral arterial disease, BP: Blood pressure, 
LDL-Cholesterol: Low density lipoprotein-cholesterol, TG: Triglycerides.
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Table IV: Distribution of Clinical Risk Index for Renovascular Hypertension according to the presence of renal artery stenosis.
Risk Factors
Group 
without RAS
(n=125) n %
Group with 
RAS
(n=59) n %
p
1. Onset of severe or stage II hypertension (blood pressure ≥ 160/100 mm Hg) after the 
age of 55 years. 7 (6%) 3 (5%) 0.88
2. Refractory or resistant hypertension, defined as inadequate blood pressure control in 
a patient who are taking to therapeutic doses of three appropriate antihypertensive 
agents (including a diuretic).
40 (32%) 12 (20%) 0.10
3. Severe hypertension with acute onset and an acute rise in blood pressure in patients 
with previously well-controlled hypertension. 21 (17%) 3 (5%) 0.02
4. A systolic-diastolic abdominal bruit that lateralizes to one side. 2 (2%) 2 (3%) 0.43
5. Patients with diffused atherosclerosis (coronary, peripheral arterial), particularly 
those over age 50 with stable creatinine level. 12 (10%) 9 (15%) 0.26
6. Onset of hypertension before the age of 30 years, particularly if there is a negative 
family history and no other risk factors for hypertension. 10 (8%) 3 (5%) 0.47
7. Patient with diffuse atherosclerosis with progressively increasing creatinine levels. 10 (8%) 5 (8%) 0.91
8. Malignant hypertension (patients with signs of end-organ-damage such as acute renal 
failure, retinal hemorrhages or papilledema, heart failure, or neurologic disturbance). 4 (3%) 0 (0%) 0.16
9. An acute elevation in the plasma creatinine concentration that occurs after the 
beginning of therapy with an angiotensin converting enzyme (ACE) inhibitor or 
angiotensin II receptor blocker (ARB). 
12 (10%) 8 (14%) 0.42
10. Unexplained creatinine elevation in patients with hypertension. 0 (0%) 4 (7%) 0.003
11. Patient with an unexplained atrophic kidney or asymmetry in renal sizes of > 1.5 cm. 6 (5%) 10 (17%) 0.006
12. Unexplained congestive heart failure or acute pulmonary edema. 0 0
RAS: Renal artery stenosis.
Table V: Distribution of patients with and without renal artery stenosis according to the potential risk factors.
Risk Factors Group without RAS
n= 125 (68%)
Group with RAS
n= 59 (32%)
Multivariate 
analysis
Age (years) 51 ± 13 58.5 ± 14.5 -
BMI (kg/m2) 31 ± 6 28 ± 4.4 -
DM n (%) 34 (27%) 25 (42%) -
CAD n (%) 17 (14%) 23 (39%) 0.03
Serum creatinine (mg/dl) 1.2 ± 0.8 1.6 ± 1.0 -
Proteinuria n (%) 56 (45%) 36 (61%) -
3rd risk Factor 21 (17%) 3 (5%) -
10th risk Factor 0 (0%) 4 (7%) -
11th risk Factor 6 (5%) 10 (17%) 0.014
RAS: Renal artery stenosis, BMI: Body mass index, DM: Diabetes Mellitus, CAD: Coronary artery disease.
Various results have been reported regarding the relationship 
between BMI and RAS. In one study, obesity was shown as a risk 
factor for atherosclerotic RAS (9). Other studies have reported 
that low BMI is a risk factor for RAS (3,4). In our study, BMI 
was found to be lower in patients with RAS. 
In a study it was shown that the prevalence of RAS decreased 
when the duration of hypertension increased (4). In our study, 
there was no relation between these two parameters.
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Some studies have suggested that use of multiple 
antihypertensive agents is a risk factor for RAS (1,19). In our 
study, no correlation was found between the two parameters. 
Only 23% of the patients whose BP was not adequately 
controlled (2nd risk factor) despite the use of three appropriate 
antihypertensive agents including diuretics had RAS. In our 
study, the 2nd risk factor was not considered to be a determinant 
for RAS.
The prevalence of RAS is high in patients with DM because 
of increased atherosclerotic vascular disease. While Ozkan 
et al. did not show any association between DM and RAS, 
Paraskevas et al. showed the presence of DM to be a risk factor 
for atherosclerotic RAS (2,9). Similar to Paraskevas, our study 
showed that the presence of DM increased the risk of RAS.
The presence of various sites of concomitant atherosclerotic 
vascular disease in hypertensive patients is a clinical marker 
for RAS. Various studies have shown that CAD in addition 
to hypertension is a clinical marker (1,3,18,17). Some studies 
have indicated that the number of vessels affected and degree 
of coronary artery stenosis are associated with RAS (9,18). 
Park et al. have determined RAS in 13.5% of their patients 
with significant CAD (17). In our study, the presence of CAD 
in addition to hypertension was found to be the strongest 
independent risk factor for RAS. We have found RAS in 57.5% 
of patients with CAD.
In some studies, PAD was specified as a risk factor for 
RAS (2,3,7,17). However, in our study, the presence of PAD in 
addition to hypertension was not identified as a risk factor. This 
difference may be due to difficulties in the diagnosis of PAD.
Some studies show that the smoking habit is a risk factor for 
atherosclerotic RAS (4, 9). Smoking in our patient population 
was not detected as a risk factor for RAS.
In various studies, an increased level of plasma creatinine 
has been shown to be a powerful marker for RAS (1,3,9,20). 
Uzu et al. found that 39% of patients with renal failure had RAS 
(18). Similarly, it was found in 44% of patients with renal failure 
in this study. Only 4 patients had the 10th risk factor. RAS was 
observed in all patients. The 10th risk factor was also found to be 
an important risk factor.
Hyperlipidemia as a risk factor for developing RAS has been 
challenged in the literature. In different studies by Park, Krijnen 
and Paraskevas, hyperlipidemia has been shown to be a clinical 
marker for RAS (4,9,17). Hansen et al. showed low HDL 
to be an independent risk factor (8). A relationship between 
hyperlipidemia and RAS was not demonstrated in Ozkan’s 
study (2). In our study, a correlation was not found between the 
lipid levels and RAS.
Proteinuria is an indicator of renal parenchyma damage in the 
presence of atherosclerotic RAS (21). In this study, the presence 
of proteinuria was seen at higher rates in patients with RAS 
compared to those without at 61% to 45% respectively. Similar 
to this study, Uzu et al. found that the presence of proteinuria 
was associated with RAS (18).
In previous studies, sudden onset or accelerated hypertension 
was defined as a risk factor regardless of age (19,20). In this 
study, the 3rd risk factor was found to have the lowest predictive 
value. Our patients 55 years or older, with severe or stage II 
hypertension (our 1st risk factor), had RAS at a rate as low as 
30%, which led to a statictically low predictive value.
The presence of an abdominal murmur was shown to be a 
marker for RAS (4). In literature, the presence of murmur was 
reported in only 45% of the patients with RAS, and in 9% of the 
patients with essential hypertension (1). In a study, abdominal 
bruits have been reported in 77.7% to 86.9% of RAS patients 
(22). We had four hypertensive patients with a murmur in the 
abdomen (4th risk factor). RAS was detected in only two of them 
with MRA. The presence of an abdominal murmur was not 
statistically significant in our study. The reason for this result 
could be that the number of patients with the 4th risk factor was 
not adequate for the study.
Diffuse atherosclerosis with stable (5th risk factor) or 
progressively increased (7th risk factor) serum creatinine levels is 
an important determinant of RAS. In this study, both risk factors 
showed similar rates for RAS, 43% and 33% respectively. These 
ratios do have determinative values, even though they are not 
statistically significant.
In our study, only 3 patients who were 30 years old without a 
family history of hypertension (6th risk factor) had RAS detected 
with MRA.
In the medical literature, RAS is closely associated with 
malignant hypertension (8th risk factor) (9,19). However, we 
were not able to demonstrate a relationship between RAS and 
the 8th risk factor. The reason for this outcome might be the low 
number of patients with the 8th risk factor.
Safian’s study showed that RAS must be suspected in cases 
of renal failure triggered by ACE inhibitors (20). We detected 
RAS in 40% of the 20 patients who had undergone renal MRA 
because of the 9th risk factor. However, this was not considered 
statistically meaningful in our study.
In previous reports, a strong correlation was reported 
between the presence of RAS and renal asymmetry (9,20,23). 
The 11th risk factor was an independent and strong marker in our 
study. Our patients with renal asymmetry had a RAS rate as high 
as 62.5%. This result was important for early diagnosis of RAS 
that could cause kidney failure.
There were no patients with the 12th (Unexplained congestive 
heart failure or acute pulmonary edema) risk factor among those 
who presented to the nephrology clinic with hypertension. The 
reason for not having any patients with the 12th risk factor in this 
study is probably that patients with congestive heart failures and 
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acute pulmenary edema tend to go directly to emergency care 
rather than the nephrology clinic.
In conclusion, the kidney sizes and parenchymal structures 
of patients with hypertension should be evaluated by imaging 
techniques for the early diagnosis of RVH. If there is more 
than 1.5 cm difference in size between the two kidneys or renal 
atrophy is present, the possibility of RVH should be considered. 
A detailed history should be obtained from hypertensive patients. 
The existence of additional CAD should be queried. Patients 
with a positive history of CAD should be noted regarding the 
possibility of RVH.
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